Backgroud Triple antiplatelet therapy with cilostazol has been known to be superior to dual antiplatelet therapy in the era of 1st generation DES implantation in terms of clinical outcome. However, it remains to be cleared whether triple antiplatelet therapy also has similar efficacy after everolimus-eluting stent implantation. Methods The study subjects were 940 patients who underwent percutaneous coronary intervention with everolimus-eluting stent (Xience V or Promus). The patients were divided into 2 groups: those treated with triple antiplatelet drugs(aspirin, clopidogrel, and cilostazol; group A, M:F=170:91, mean age=65짹11yrs) and those with dual antiplatelet drugs(aspirin and clopidogrel; group B, M:F=422:257, mean age=64짹11yrs). The incidences of various major adverse cardiac events were compared between group A and B. Total MACE was defined as a composite of total death, nonfatal MI, repeated revascularization. Results There was no significant difference in the incidence of major bleeding between 2 groups. Compared with group B, group A showed no significant differences in cardiac death(adjusted odds ratio, 1.144; 95% CI, 0.205-6.394; p=0.878), total death(adjusted odds ratio, 0.616; 95% CI, 0.193-1.969; p=0.414) and total MACE(adjusted odds ratio, 0.499; 95% CI, 0.246-1.011; p=0.054). Conclusions Triple antiplatelet therapy has no beneficial effect in clinical outcome compared to dual antiplatelet therapy in patients with everolimus-eluting stent implantation.